Ovarian Cancer Biomarker Research Act of 2009
Latest action · Mar 31, 2009 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 31, 2009
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Ovarian Cancer Biomarker Research Act of 2009 - Amends the Public Health Service Act to require the Director of the National Cancer Institute to enter into cooperative agreements with, or make grants to, public or nonprofit entities to establish and operate Ovarian Cancer Biomarker Centers of Excellence to conduct research on biomarkers for use in risk stratification for, and the early detection and screening of, ovarian cancer. Permits federal funds to be used for research on: (1) the development and characterization of new biomarkers and the refinement of existing biomarkers, for ovarian cancer; (2) the clinical and laboratory validation of such biomarkers; (3) the development and implementation of clinical and epidemiological research on the utilization of such biomarkers; and (4) the development and implementation of repositories for new tissue, urine, serum, and other biological specimens.
Requires the Director to: (1) make available for research banked serum and tissue specimens from clinical research regarding ovarian cancer that was funded by the Department of Health and Human Services (HHS); and (2) establish an Ovarian Cancer Biomarker Clinical Trial Committee to assist in designing and implementing national clinical trials to determine the utility of using such biomarkers. Requires a national data center to be established in and supported by the Institute to conduct statistical analyses of trial data, and to store such analyses and data. Requires such data and statistical analyses to be used to establish clinical guidelines to provide the medical community with information regarding the use of validated biomarkers.
Cosponsors 2
Members who signed on, in the order they did. Signatures ran from Jul 13, 2009 to Sep 9, 2009.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | Dianne Feinstein | Jul 13, 2009 | |
| D-NY | Charles E. Schumer | Sep 9, 2009 |
Actions 3
Everything that happened, newest first.
- Mar 31, 2009Introduced in Senate
- Mar 31, 2009Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Mar 31, 2009Sponsor introductory remarks on measure. (CR S4080-4081)
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 1816 | Ovarian Cancer Biomarker Research Act of 2009 | Related bill | Apr 1, 2009 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Cancer
- Department of Health and Human Services
- Health
- Health information and medical records
- Health programs administration and funding
- Health promotion and preventive care
- Medical research
- Medical tests and diagnostic methods
- National Institutes of Health (NIH)
- Sex and reproductive health
- Women's health
Text 1
Each version as it was printed, newest first.
- Mar 31, 2009Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.